Axis Bank has approved a capital infusion of ₹15 billion (₹1,500 crore) into its wholly-owned subsidiary, Axis Finance Limited. The investment will be executed via a Rights Issue in one or more tranches before March 31, 2027, providing growth capital for the NBFC arm.
The Board’s Acquisitions, Divestments, and Merger Committee sanctioned the proposal, which has already received approval from the Reserve Bank of India. The infusion is aimed at strengthening Axis Finance’s balance sheet, supporting expansion, and enhancing its ability to serve retail and corporate borrowers.
Market Impact
Axis Finance, a non-banking financial company (NBFC), plays a critical role in Axis Bank’s diversified financial services portfolio. The capital infusion will enable the subsidiary to scale lending operations, improve competitiveness, and tap into new growth opportunities in India’s evolving credit market.
Key Highlights
-
Axis Bank approves ₹15 billion infusion into Axis Finance Limited
-
Capital to be raised through Rights Issue in tranches by March 2027
-
RBI has already cleared the proposal
-
Infusion classified as a related party transaction since AFL is wholly owned
-
Funds to strengthen NBFC arm’s growth and lending capacity
Outlook For Investors
Analysts view this move as a proactive step to bolster Axis Finance’s capital adequacy and growth trajectory. With NBFCs playing a vital role in India’s credit ecosystem, the infusion positions Axis Finance to capture rising demand for retail and corporate lending while aligning with Axis Bank’s long-term strategy.
Sources: InvestyWise, Business Upturn